Anzeige
Meldung des Tages: Gold auf 6.300 USD? Diese Aktie könnte der geheime Hebel sein

Actinium Pharmaceuticals News

Aktie
WKN:  A2QA48 ISIN:  US00507W2061 US-Symbol:  ATNM Branche:  Biotechnologie Land:  USA
1,10 $
+0,00 $
0,00%
0,9321 € 18:38:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
40,29 Mio. €
Streubesitz
77,78%
KGV
-1,31
Index-Zuordnung
-

Actinium Pharmaceuticals News

16.05.25 - PR Newswire
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM PR Newswire
13.05.25 - PR Newswire
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
12.05.25 - PR Newswire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
12.05.25 - PR Newswire
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNM
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNM PR Newswire
08.05.25 - PR Newswire
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
07.05.25 - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium PR Newswire
06.05.25 - PR Newswire
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
06.05.25 - PR Newswire
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky PR Newswire
05.05.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders PR Newswire
04.05.25 - PR Newswire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
02.05.25 - PR Newswire
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM PR Newswire
01.05.25 - PR Newswire
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To ...
01.05.25 - PR Newswire
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM)
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM) PR Newswire
30.04.25 - PR Newswire
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation PR Newswire
29.04.25 - PR Newswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
28.04.25 - PR Newswire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
28.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
28.04.25 - PR Newswire
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American ...

Newssuche

Videos

newspaper
07.04.26 +0,99%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »